Publication: Cytotoxicity study on the combination of cisplatin and gallic acid on cervical cancer cells (hela)
No Thumbnail Available
Date
2025-01
Authors
Ramlan, Nur Iman Nafisa
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Cervical cancer is the fourth most common cancer among women worldwide and remains a major health concern. Cisplatin, a chemotherapeutic agent, is often limited by severe side effects and the development of resistance. Combining cisplatin with natural compounds, such as gallic acid, may enhance therapeutic efficacy while reducing toxicity. This study aimed to evaluate the cytotoxic and anti-migratory effects of cisplatin combined with gallic acid on cervical cancer cells (HeLa). Cytotoxicity was assessed using the MTT assay the half-maximal inhibitory concentration (IC50). Serial dilution of cisplatin, starting from its IC50 was combined with a fixed concentration of gallic acid at its IC50. The combination effects were analyzed using CompuSyn software to assess potential synergy, additivity, or antagonism. The combination with the greatest synergistic effect was then chosen for wound healing assay, to examine the anti-migratory effects of the combination. The IC50 of cisplatin and gallic acid for HeLa cells were 25.12 μg/mL and 85.70 μg/mL, after 24 hours, which decreased to 1.786 μg/mL and 13.27 μg/mL at 48 hours. For WRL-68 cells, the IC50 values of cisplatin and gallic acid were 28.02 μg/mL and >100 μg/mL at 24 hours, decreasing to 8.842 μg/mL and 21.06 μg/mL at 48 hours. All combinations of cisplatin and gallic acid significantly inhibited HeLa cell proliferation with combination index values below 1, indicating a synergistic effect. Furthermore, the combination exhibited anti-migratory effects, showing the lowest percentage of wound closure compared to control and single treatment groups. These findings suggest that combining cisplatin with gallic acid holds potential as a novel therapeutic strategy to enhance cervical cancer treatment outcomes
Description
Keywords
-